Skip to main content

Table 7 Multivariate analysis including patients who received stereotactic radiotherapy with dose/fractionation data (n = 1739)

From: Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis

  Hazard Ratio 95% Confidence Interval p-value
Sex Male 1.00 Ref 0.001
Female 0.82 0.73–0.92
Age 18–59 1.00 Ref 0.01
60–69 1.12 0.97–1.29
70–79 1.27 1.09–1.48
80+ 1.35 1.04–1.76
Comorbidity 0 1.00 Ref 0.004
1 1.02 0.89–1.18
> 2 1.41 1.15–1.73
Histology Adenocarcinoma 1.00 Ref < 0.0001
Non-adenocarcinoma 1.29 1.14–1.45
Race White 1.00 Ref 0.52
Non-white 1.05 0.90–1.23
Insurance Uninsured 1.00 Ref 0.77
Insured 0.95 0.69–1.32
Facility Type Academic 1.00 Ref 0.17
Nonacademic 1.09 0.97–1.22
Systemic Therapy Chemotherapy 1.00 Ref 0.51
Immunotherapy 1.08 0.86–1.37
Biologically Effective Dose ≤60 Gy 1.00 Ref < 0.0001
> 60 Gy 0.79 0.70–0.90